Baseline characteristics of the patients
. | Group A, val/gan; n = 26 . | Group B, gan/val; n = 22 . |
|---|---|---|
| Age, y* | 44.7 ± 12.91 | 44.9 ± 12.60 |
| Male sex, no. (%) | 15 (57.7) | 15 (68.2) |
| Ethnic origin, no. (%) | ||
| White | 26 (100) | 21 (95.5) |
| Other | 0 (0.0) | 1 (4.5) |
| Body mass index, kg/m2* | 23.3 ± 3.96 | 23.2 ± 3.39 |
| Intestinal GVHD, no. (%) | 3 (11.5) | 3 (13.6) |
| Day of randomization after transplantation, d | 51.5 ± 36.98 | 41.7 ± 13.91 |
| CMV status donor/recipient, no. (%) | ||
| Positive/positive | 17 (65.4) | 12 (54.5) |
| Positive/negative | 1 (3.8) | 3 (13.6) |
| Negative/positive | 8 (30.8) | 7 (31.8) |
| Donor/recipient relationship, no. (%)† | ||
| HLA-identical sibling donor | 14 (53.8) | 8 (36.4) |
| Matched unrelated donor | 9 (34.6) | 9 (40.9) |
| Mismatched related donor | 0 (0.0) | 2 (9.1) |
| Mismatched unrelated donor | 3 (11.5) | 2 (9.1) |
| Nonmyeloablative low intensity SCT, no. (%) | 6 (23.1) | 6 (27.3) |
| CMV-M positive, no.(%) | 24 (92.3) | 21 (95.5) |
. | Group A, val/gan; n = 26 . | Group B, gan/val; n = 22 . |
|---|---|---|
| Age, y* | 44.7 ± 12.91 | 44.9 ± 12.60 |
| Male sex, no. (%) | 15 (57.7) | 15 (68.2) |
| Ethnic origin, no. (%) | ||
| White | 26 (100) | 21 (95.5) |
| Other | 0 (0.0) | 1 (4.5) |
| Body mass index, kg/m2* | 23.3 ± 3.96 | 23.2 ± 3.39 |
| Intestinal GVHD, no. (%) | 3 (11.5) | 3 (13.6) |
| Day of randomization after transplantation, d | 51.5 ± 36.98 | 41.7 ± 13.91 |
| CMV status donor/recipient, no. (%) | ||
| Positive/positive | 17 (65.4) | 12 (54.5) |
| Positive/negative | 1 (3.8) | 3 (13.6) |
| Negative/positive | 8 (30.8) | 7 (31.8) |
| Donor/recipient relationship, no. (%)† | ||
| HLA-identical sibling donor | 14 (53.8) | 8 (36.4) |
| Matched unrelated donor | 9 (34.6) | 9 (40.9) |
| Mismatched related donor | 0 (0.0) | 2 (9.1) |
| Mismatched unrelated donor | 3 (11.5) | 2 (9.1) |
| Nonmyeloablative low intensity SCT, no. (%) | 6 (23.1) | 6 (27.3) |
| CMV-M positive, no.(%) | 24 (92.3) | 21 (95.5) |